Skip to content
Baltimore News Journal – Lifestyle
Author:
Xenetic Biosciences, Inc.
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
June 1, 2026
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
May 13, 2026
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
April 22, 2026
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
March 13, 2026